Litigation Details for AZURITY PHARMACEUTICALS, INC. v. BIONPHARMA INC. (D. Del. 2021)
✉ Email this page to a colleague
AZURITY PHARMACEUTICALS, INC. v. BIONPHARMA INC. (D. Del. 2021)
| Docket | ⤷ Try a Trial | Date Filed | 2021-09-10 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 15:1126 Patent Infringement | Assigned To | Leonard Philip Stark |
| Jury Demand | Plaintiff | Referred To | |
| Patents | 10,039,745; 10,154,987; 6,028,222; 6,977,257; 8,008,006; 8,568,747; 8,778,366; 9,000,011; 9,463,183; 9,616,096; 9,669,008; 9,808,442; 9,855,214; 9,968,553 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in AZURITY PHARMACEUTICALS, INC. v. BIONPHARMA INC.
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Biologic Drugs cited in AZURITY PHARMACEUTICALS, INC. v. BIONPHARMA INC.
The biologic drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for AZURITY PHARMACEUTICALS, INC. v. BIONPHARMA INC. (D. Del. 2021)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2021-12-13 | 103 | Products (Nov. 2003, Rev. 2; and (5) U.S. Patent No. 8,568,747 B1. A POSA would be motivated to combine…Products (Nov. 2003, Rev. 2; and (5) U.S. Patent No. 8,568,747 B1. A POSA would be motivated to combine…. Del.). 5 U.S. Patent Nos. 11,040,023 (“’023 patent”) and 11,141,405 (“’405 patent”) (collectively, …for patent infringement of United States Patent Nos. 11,040,023 (the “’023 patent”) and…“’405 patent”) (collectively the “Patents-in-Suit”) and damages under the patent laws | External link to document | |
| 2021-12-21 | 109 | 6/2012 Nov. 2, 2017, now Pat. No. 10,039,745, which is a WO WO-2014055667 …Reference-based pricing of prescription drugs: 10,039,745 B2 8/2018 Mosher … O U.S. Pat. No. 10,039,745, issued Aug. 7, 2018), which is a …action for patent infringement of United States Patent Nos. 11,040,023 (the “’023 patent”) and 11,141,405…11,141,405 (the “’405 patent”) (collectively the “Patents-in-Suit”) and damages under the patent laws of the | External link to document | |
| 2022-02-24 | 137 | Redacted Document | Thereafter, U.S. Patent Nos. 9,808,442 B2 (“’442 patent,” 18-1962 D.I. 1-1, Compl. Ex. B), 10,039,745 B2 (“’745… or more claims of U.S. Patent No. 11,040,023 (the “’023 patent”) (the “Patent- In-Suit”). Upon information….S. Patent Application No. 17,228,024, which issued as U.S. Patent No. 11,141,405 (“’405 patent”) on…and ’987 patents are patentably indistinct from, and cover essentially the same patentable subject matter…, the ’008 patent. 123. The claims of the Second Wave Patents are patentably indistinct | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
